Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3% – Time to Sell?

Shares of Jyong Biotech Ltd. (NASDAQ:MENS) fell 12.3% during trading on Wednesday . The stock traded as low as $2.42 and last traded at $2.42. 301,403 shares changed hands during trading, a decline of 34% from the average session volume of 458,348 shares. The stock had previously closed at $2.76.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Jyong Biotech Trading Down 12.3%

The stock’s 50-day moving average is $2.90 and its 200-day moving average is $30.25.

Jyong Biotech (NASDAQ:MENS) last released its quarterly earnings data on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Jyong Biotech

A number of large investors have recently modified their holdings of MENS. China Universal Asset Management Co. Ltd. acquired a new position in Jyong Biotech during the 4th quarter worth approximately $49,000. Man Group plc acquired a new position in shares of Jyong Biotech during the fourth quarter worth $56,000. BNP Paribas Financial Markets purchased a new position in shares of Jyong Biotech in the third quarter valued at $67,000. Millennium Management LLC increased its stake in Jyong Biotech by 209.4% during the 4th quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock worth $159,000 after buying an additional 27,245 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Jyong Biotech by 19.6% in the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after buying an additional 10,538 shares in the last quarter.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.